-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-09-22
Zhao and colleagues describe a standardized whole-blood stimulation protocol for measuring how metabolic interventions reshape cytokine responses to defined immune stimuli. By preserving the multicellular blood environment while controlling stimulation, inhibition, sample handling, and cytokine quantification, the method provides a practical framework for cohort studies and mechanistic immunometabolism research.
-
DiscoveryProbe FDA-approved Drug Library Workflow
2026-09-22
Build a mechanism-aware screening workflow around a clinically annotated compound collection rather than relying on phenotype alone. The DiscoveryProbe library pairs ready-to-use 10 mM DMSO stocks with live-cell mTORC1 sensing, orthogonal validation, and practical troubleshooting for drug repositioning screening and cancer research.
-
Adipose-Neural Axis in Cardiac Arrhythmias
2026-09-21
Fan et al. establish a stem cell-based coculture model showing how epicardial adipose tissue can communicate with sympathetic neurons and cardiomyocytes through a leptin–NPY pathway. The study identifies Y1R, NCX, and CaMKII as mechanistically connected intervention points while linking increased EAT thickness and circulating leptin/NPY levels with atrial fibrillation.
-
GSK126 EZH2 inhibitor: Assay Guide
2026-09-21
A scenario-based guide to using GSK126 EZH2 inhibitor (SKU A3446) in viability, proliferation, and cancer epigenetics research. It connects EZH2 biology with practical decisions about dosing, solvent controls, time courses, readout interpretation, and product selection.
-
Standardized Whole-Blood Stimulation in Immunometabolism
2026-09-20
The reference study presents a standardized whole-blood stimulation protocol that combines pathogen- or pattern-recognition receptor-derived stimuli with pharmacological metabolism modulation. Its main contribution is a reproducible framework for measuring how metabolic pathways selectively reshape cytokine responses while preserving the cellular and plasma context of human blood.
-
RITA: Interpreting Cell-Killing Data in Cancer Models
2026-09-18
RITA (NSC 652287) is an MDM2-p53 interaction inhibitor with distinctive activity in renal carcinoma research. This guide shows how to separate growth inhibition from true cell killing so RITA data are interpreted more rigorously across apoptosis assays and tumor xenograft models.
-
FOXM1–ERα Network in Female Lung Adenocarcinoma
2026-09-18
The reference study integrates transcriptomic, survival, immune, and experimental analyses to identify FOXM1 as a clinically relevant factor in female lung adenocarcinoma and proposes a DGCR5–miR-204-5p–FOXM1–ERα regulatory network. Its findings provide a hypothesis-generating framework for biomarker studies, although the ceRNA relationships and FOXM1–ERα mechanism require further validation in independent cohorts and models.
-
Hoechst 33258 for Tumor Cell Imaging
2026-09-17
Hoechst 33258 adds a cell-permeable nuclear readout to confocal, flow cytometry, and optical-tweezers studies of tumor heterogeneity. Its DNA signal supports segmentation, cell-cycle-aware interpretation, and live-versus-fixed comparisons without being mistaken for a direct KRas-transfer reporter.
-
Pazopanib: ATRX-Aware RTK Assay Design
2026-09-17
Pazopanib (GW-786034) is a multi-targeted RTK inhibitor for dissecting angiogenesis, VEGF signaling, and genotype-dependent tumor responses. This article translates ATRX-deficient glioma findings into a rigorous framework for selecting controls, endpoints, and combination assays in cancer research.
-
HDAC Inhibition Reverses EBV-Driven NPC Plasticity
2026-09-16
The reference study identifies an EBV LMP1–STAT5A–HDAC1/2 pathway that suppresses CEBPA and drives dedifferentiation in nasopharyngeal carcinoma. Its xenograft experiments show that HDAC inhibition can restore CEBPA-associated differentiation, providing a mechanistic basis for targeting tumor-cell plasticity in solid malignancy.
-
CRISPR DNA Repair Pathway Choice by Drug Repurposing
2026-09-16
Macak, Kanis, and Riesenberg present a large phenotypic screen showing that clinically approved drugs can shift the mutational outcomes of CRISPR-induced DNA double-strand breaks toward NHEJ, MMEJ, or HDR. The study also identifies ESR2 and AOX1 as regulators of repair-associated biology and highlights drug combinations that may support genome editing, disease modeling, and synthetic-lethal cancer strategies.
-
Nimbolide, RNF114, and Targeted Protein Degradation
2026-09-15
Spradlin and colleagues used activity-based protein profiling to identify RNF114 as a covalent target of the anti-cancer natural product nimbolide and to define a cysteine involved in substrate recognition. The study also shows how this interaction can be redirected toward targeted protein degradation, providing a mechanistic link between natural-product chemistry, ubiquitin biology, and degrader design.
-
Separating Growth Arrest from Cell Death in Cancer Assays
2026-09-15
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures in cancer drug evaluation. By separating proliferative arrest from cell killing and considering their different timing, the work provides a more interpretable framework for in vitro cancer research and response profiling.
-
DiscoveryProbe FDA-approved Drug Library for Target Screens
2026-09-14
Use the DiscoveryProbe FDA-approved Drug Library to move from mechanism-driven assays to clinically relevant compound testing without assembling a fragmented collection. Its ready-to-screen format supports drug repositioning screening, interaction assays, phenotypic profiling, and orthogonal validation across disease models.
-
Repurposed Vitamins Against SARS-CoV-2 Targets
2026-09-14
The reference study used virtual screening, molecular docking, and molecular dynamics to evaluate vitamins against two SARS-CoV-2 vulnerabilities: the spike receptor-binding domain and 3CL protease. Its strongest contribution is a dual-target computational framework that connects possible inhibition of viral entry with disruption of polyprotein processing, while its predictions remain hypotheses requiring biochemical and cellular validation.